<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982655</url>
  </required_header>
  <id_info>
    <org_study_id>KY20162085-2</org_study_id>
    <nct_id>NCT02982655</nct_id>
  </id_info>
  <brief_title>Controlling Hypertension After Severe Cerebrovascular Event</brief_title>
  <acronym>CHASE</acronym>
  <official_title>A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanzhong Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an University Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this academic lead study is to explore ideal blood pressure targets and
      optimum individualized anti-hypertension strategies in acute severe stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Of high mortality and morbidity, severe stroke is associated with devastating damages in
      neurologic, respiratory, circulatory and many other systems. The outcomes of patients with
      severe stroke depend largely on medical strategies on acute stage, especially on blood
      pressure (BP) management. Unfortunately, so far no ideal BP range has been scientifically
      determined for patients with acute severe stroke.

      The CHASE study aims to provide reliable data on the effects of individualized
      anti-hypertension strategy in patients with acute severe stroke (target recruitment 250)
      compared to standard guideline-based management of BP (target recruitment 250). Patients
      presenting with acute (&lt;72h) severe stroke (GCS ≦ 12 or NIHSS ≧ 11) and elevated BP (systolic
      blood pressure ≧150 mmHg or diastolic blood pressure ≧ 100 mmHg) will be randomly assigned to
      individualized anti-hypertension treatment or guideline-based treatment for 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or major disability (defined by the modified Rankin scale)</measure>
    <time_frame>3 months after onset</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death or major disability (defined by the modified Rankin scale)</measure>
    <time_frame>14 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale</measure>
    <time_frame>14 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale</measure>
    <time_frame>3 months after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hypotension</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood coagulation disorder</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events That Are Related to Treatment</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Severe Stroke</condition>
  <condition>Acute Stroke</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Individualized BP lowering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Management policy is to lower the systolic or diastolic BP by 10-15% within 24 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guideline recommended BP lowering</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP &gt; 200 mmHg or diastolic BP &gt;110 mmHg in patients with ischemic stroke, and systolic BP &gt; 180 mmHg or diastolic BP &gt; 110 mmHg in patients with cerebral hemorrhage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood pressure management policies</intervention_name>
    <arm_group_label>Individualized BP lowering</arm_group_label>
    <arm_group_label>Guideline recommended BP lowering</arm_group_label>
    <other_name>Labetalol Hydrochloride</other_name>
    <other_name>Metoprolol tartrate</other_name>
    <other_name>Hydralazine Hydrochloride</other_name>
    <other_name>Glycerol Trinitrate</other_name>
    <other_name>Phentolamine mesylate</other_name>
    <other_name>Nicardipine</other_name>
    <other_name>Urapidil</other_name>
    <other_name>Esmolol</other_name>
    <other_name>Clonidine</other_name>
    <other_name>Enalaprilat</other_name>
    <other_name>nitroprusside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe stroke occurred in 72 hours.

          -  GCS ≤12 or NIHSS≥11.

          -  Systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg on
             admission.

          -  Able to be 'actively' treated and admitted to a monitored facility.

          -  Informed consent.

        Exclusion Criteria:

          -  Received intravenous thrombolytic therapy.

          -  Concurrent severe heart failure.

          -  Concurrent acute myocardial infarction.

          -  Concurrent unstable angina.

          -  Concurrent severe systemic diseases.

          -  Other serious or life-threatening disease before the stroke.

          -  Clear indication, in the clinician's view, for antihypertensive therapy during the
             acute phase of stroke (i.e. multiple cerebral artery stenosis, apparent
             cerebrovascular malformation or aortic dissection, or other situations).

          -  Patient unavailable for follow-up (e.g. no fixed address).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Jiang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurology, Xijing Hospital, Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen Jiang, PhD</last_name>
    <phone>86-029-84771319</phone>
    <email>jiangwen@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fang Yang, PhD</last_name>
    <phone>86-029-84771319</phone>
    <email>fyangx@fmmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankang Central Hospital</name>
      <address>
        <city>Ankang</city>
        <state>Shaanxi</state>
        <zip>725000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingsheng Wang, MD</last_name>
      <email>1327019765@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yi Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanzhong Central Hospital</name>
      <address>
        <city>Hanzhong</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Chen, MD</last_name>
      <email>297379495@qq.com</email>
    </contact>
    <investigator>
      <last_name>Kangjun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shangluo Central Hospital</name>
      <address>
        <city>Shangluo</city>
        <state>Shaanxi</state>
        <zip>726000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Li, MD</last_name>
      <email>929031470@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jun Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an 141 Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongjing Zhu, MD</last_name>
      <email>zdjkx@sina.com</email>
    </contact>
    <investigator>
      <last_name>Qiuwu Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Jiang, PhD</last_name>
      <phone>86-029-84771319</phone>
      <email>jiangwen@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Fang Yang, PhD</last_name>
      <phone>86-029-84771319</phone>
      <email>fyangx@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Guo, MD</last_name>
      <email>1443291624@qq.com</email>
    </contact>
    <investigator>
      <last_name>Wei Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Huo, MD</last_name>
      <email>huokangster@qq.com</email>
    </contact>
    <investigator>
      <last_name>Kang Huo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Di, MD</last_name>
      <email>312180404@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hua Lv, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xianyang Central Hospital</name>
      <address>
        <city>Xianyang</city>
        <state>Shaanxi</state>
        <zip>712000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Han, MD</last_name>
      <phone>+8615399259050</phone>
    </contact>
    <investigator>
      <last_name>Changhu Xue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>215 Hospital of Shaanxi NI</name>
      <address>
        <city>Xianyang</city>
        <state>Shaanxi</state>
        <zip>712021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingfeng Wu, MD</last_name>
      <email>peakwu72@126.com</email>
    </contact>
    <investigator>
      <last_name>Feng Fu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yulin No.2 Hospital</name>
      <address>
        <city>Yulin</city>
        <state>Shaanxi</state>
        <zip>719000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feihu Chang, MD</last_name>
      <email>309998611@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaocheng Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011 Feb 26;377(9767):741-50. doi: 10.1016/S0140-6736(11)60104-9.</citation>
    <PMID>21316752</PMID>
  </reference>
  <reference>
    <citation>Vemmos KN, Spengos K, Tsivgoulis G, Zakopoulos N, Manios E, Kotsis V, Daffertshofer M, Vassilopoulos D. Factors influencing acute blood pressure values in stroke subtypes. J Hum Hypertens. 2004 Apr;18(4):253-9.</citation>
    <PMID>15037874</PMID>
  </reference>
  <reference>
    <citation>AlSibai A, Qureshi AI. Management of Acute Hypertensive Response in Patients With Ischemic Stroke. Neurohospitalist. 2016 Jul;6(3):122-9. doi: 10.1177/1941874416630029. Epub 2016 Apr 21.</citation>
    <PMID>27366297</PMID>
  </reference>
  <reference>
    <citation>Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR.0b013e318284056a. Epub 2013 Jan 31.</citation>
    <PMID>23370205</PMID>
  </reference>
  <results_reference>
    <citation>CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 Jun 7;349(9066):1641-9.</citation>
    <PMID>9186381</PMID>
  </results_reference>
  <results_reference>
    <citation>Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Hussein HM, Divani AA, Reddi AS. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med. 2007 Jan;25(1):32-8.</citation>
    <PMID>17157679</PMID>
  </results_reference>
  <results_reference>
    <citation>Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004 Feb;35(2):520-6. Epub 2004 Jan 15.</citation>
    <PMID>14726553</PMID>
  </results_reference>
  <results_reference>
    <citation>Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003 Jul;34(7):1699-703. Epub 2003 Jun 19.</citation>
    <PMID>12817109</PMID>
  </results_reference>
  <results_reference>
    <citation>Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009 Jan;8(1):48-56. doi: 10.1016/S1474-4422(08)70263-1. Epub 2008 Dec 4.</citation>
    <PMID>19058760</PMID>
  </results_reference>
  <results_reference>
    <citation>Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, Poulter NR; COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010 Aug;9(8):767-75. doi: 10.1016/S1474-4422(10)70163-0.</citation>
    <PMID>20621562</PMID>
  </results_reference>
  <results_reference>
    <citation>He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, Tong W, Liu C, Xu T, Ju Z, Peng Y, Peng H, Li Q, Geng D, Zhang J, Li D, Zhang F, Guo L, Sun Y, Wang X, Cui Y, Li Y, Ma D, Yang G, Gao Y, Yuan X, Bazzano LA, Chen J; CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014 Feb 5;311(5):479-89. doi: 10.1001/jama.2013.282543.</citation>
    <PMID>24240777</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008 May;7(5):391-9. doi: 10.1016/S1474-4422(08)70069-3. Epub 2008 Apr 7.</citation>
    <PMID>18396107</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013 Jun 20;368(25):2355-65. doi: 10.1056/NEJMoa1214609. Epub 2013 May 29.</citation>
    <PMID>23713578</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Stroke</keyword>
  <keyword>Acute Stroke</keyword>
  <keyword>Antihypertension</keyword>
  <keyword>mortality</keyword>
  <keyword>disability</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

